Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia. The company offers supplements for immunity and vitality, health and wellbeing, metabolic and cardiovascular health, and beauty and physical comfort. It also develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; and TOTUM-448 for the reduction of hepatic steatosis. Additionally, the company offers e-commerce delivery service in Belgium and Luxembourg. Valbiotis SA was incorporated in 2014 and is based in Périgny, France.
Frequently asked questions
What sector does Valbiotis SAS (ALVAL) operate in?
Valbiotis SAS belongs to the Healthcare sector and operates in the Packaged Foods industry.
What is Valbiotis SAS (ALVAL) current stock price?
As of the latest data, Valbiotis SAS stock price is €0.86, with a previous close of €0.87. Valbiotis SAS lost -€0.01 in the last trading session, representing a -0.69% loss.
What is Valbiotis SAS (ALVAL) current market capitalization?
Valbiotis SAS market cap is approximately 30.63 million.
What is Valbiotis SAS (ALVAL) Earnings Per Share (EPS)?
The trailing EPS is -€0.46, and the forward EPS is -€0.08.
Does Valbiotis SAS (ALVAL) pay dividends?
No. Valbiotis SAS does not pay a dividend.
What is Valbiotis SAS (ALVAL) beta (volatility) score?
Valbiotis SAS has a beta of -0.203, indicating lower volatility than the overall market.
